On June 19, 2019 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported the pricing of an underwritten public offering of 5,900,000 shares of its common stock at a price to the public of $17.00 per share (Press release, Kura Oncology, JUN 19, 2019, View Source [SID1234537159]). Kura has granted the underwriters a 30-day option to purchase up to an additional 885,000 shares of its common stock. The offering is expected to close on or about June 21, 2019, subject to customary closing conditions. The gross proceeds to Kura from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be $100.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Kura.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SVB Leerink and Cowen are acting as joint book-running managers for the offering. Wedbush PacGrow and Oppenheimer & Co. are acting as co-lead managers, and H.C. Wainwright & Co. is acting as co-manager for the offering.

The securities described above are being offered by Kura pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kura with the Securities and Exchange Commission (the "SEC") and that was declared effective on November 21, 2018. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at View Source Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email at [email protected], or Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (631) 592-5973, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.